Download Files:
Varlitinib
SKU
HY-10530-10 mg
Category Reference compound
Tags Cancer, EGFR, JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
$132 – $858
Products Details
Product Description
– Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively[1].
Web ID
– HY-10530
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C22H19ClN6O2S
References
– [1]Hsieh C, et al. Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models. Journal of Clinical Oncology 34, no. 15_suppl|[2]Miknis G, et al. ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2.Proc Amer Assoc Cancer Res, Volume 46, 2005
CAS Number
– 845272-21-1
Molecular Weight
– 466.94
Compound Purity
– 98.03
SMILES
– C[C@H]1N=C(NC2=CC3=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)N=CN=C3C=C2)OC1
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– EGFR
Isoform
– EGFR/ErbB1/HER1;ErbB2/HER2;ErbB4/HER4
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.